Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/74
A61L-017/10
D01F-006/62
A61L-031/06
A61L-031/14
B29C-055/00
D01F-008/14
B29K-073/00
B29L-031/00
출원번호
US-0964985
(2015-12-10)
등록번호
US-9555155
(2017-01-31)
발명자
/ 주소
Ganatra, Amit
Felix, Fabio
Shah, Bhavin
Bernasconi, Matthew
Rizk, Said
Martin, David P.
Williams, Simon F.
출원인 / 주소
Tepha, Inc.
대리인 / 주소
Pabst Patent Group LLP
인용정보
피인용 횟수 :
0인용 특허 :
144
초록▼
Resorbable multifilament yarns and monofilament fibers including poly-4-hydroxybutyrate and copolymers thereof with high tenacity or high tensile strength have been developed. The yarns and fibers are produced by cold drawing the multifilament yarns and monofilament fibers before hot drawing the yar
Resorbable multifilament yarns and monofilament fibers including poly-4-hydroxybutyrate and copolymers thereof with high tenacity or high tensile strength have been developed. The yarns and fibers are produced by cold drawing the multifilament yarns and monofilament fibers before hot drawing the yarns and fibers under tension at temperatures above the melt temperature of the polymer or copolymer. These yarns and fibers have prolonged strength retention in vivo making them suitable for soft tissue repairs where high strength and strength retention is required. The multifilament yarns have tenacities higher than 8.1 grams per denier, and in vivo, retain at least 65% of their initial strength at 2 weeks. The monofilament fibers retain at least 50% of their initial strength at 4 weeks in vivo. The monofilament fibers have tensile strengths higher than 500 MPa. These yarns and fibers may be used to make various medical devices for various applications.
대표청구항▼
1. A multifilament yarn or monofilament fiber comprising a 4-hydroxybutyrate polymer or copolymer wherein the yarn has one or more properties selected from the group consisting of: a tenacity greater than 8.1 grams per denier but less than 12 grams per denier; an elongation to break of between 10% t
1. A multifilament yarn or monofilament fiber comprising a 4-hydroxybutyrate polymer or copolymer wherein the yarn has one or more properties selected from the group consisting of: a tenacity greater than 8.1 grams per denier but less than 12 grams per denier; an elongation to break of between 10% to 30%; and a denier per filament between 1.7 and 9.0, and wherein the monofilament fiber has one or more properties selected from the group consisting of: a tensile strength between 500 MPa and 1,500 MPa; a Young's Modulus of less than 2 GPa and an elongation to break of 15% to 120%, wherein the multifilament yarn or monofilament fiber is produced by a method comprising (a) spinning a multifilament yarn or monofilament fiber comprising a 4-hydroxybutyrate polymer or copolymer, and (b) cold drawing the multifilament yarn or monofilament fiber, wherein the multifilament yarn or monofilament fiber is hot drawn after cold drawing at a temperature above the melt temperature of the polymer or copolymer, wherein the monofilament fiber is cold drawn with an orientation ratio of 3 to 4, and then hot drawn in one or more subsequent draws; or,wherein the multifilament yarn or monofilament fiber is produced by a method comprising: (a) producing the polymer with a recombinant E. coli cell culture, (b) extracting and purifying the polymer from the biomass, (c) spinning the multifilament yarn or monofilament fiber from the polymer, (d) cold drawing the multifilament yarn or monofilament fiber, (e) hot drawing the multifilament yarn or monofilament fiber after cold drawing at a temperature above the melt temperature of the polymer or copolymer, and (f) optionally relaxing and/or annealing the multifilament yarn or monofilament fiber, wherein the multifilament yarn or monofilament fiber is biocompatible. 2. The monofilament fiber of claim 1, wherein the fiber has been allowed time to crystallize before drawing. 3. The monofilament yarn of claim 1, wherein the yarn has been oriented in a multi-stage orientation process. 4. The multifilament yarn of claim 3, wherein the yarn is cold drawn in the first stage of the multi-stage orientation process. 5. The monofilament fiber of claim 1, wherein the monofilament fiber has been drawn at a temperature below 50° C., before being drawn at a temperature above the melt temperature of the fiber. 6. A medical device comprising the multifilament yarn or the monofilament fiber of claim 1, wherein the device is a suture, monofilament suture, multifilament suture, braided suture, hybrid suture of monofilament and multifilament fibers, barbed suture, self-retaining suture, braid, ligature, tape, knitted or woven mesh, non-woven mesh, knitted tube, monofilament mesh, multifilament mesh, patch, wound healing device, bandage, wound dressing, burn dressing, ulcer dressing, skin substitute, hemostat, tracheal reconstruction device, organ salvage device, dural substitute, dural patch, nerve regeneration or repair device, hernia repair device, hernia mesh, hernia plug, device for temporary wound or tissue support, tissue engineering scaffold, guided tissue repair/regeneration device, anti-adhesion membrane, adhesion barrier, tissue separation membrane, retention membrane, sling, device for pelvic floor reconstruction, urethral suspension device, device for treatment of urinary incontinence, device for treatment of vesicoureteral reflux, bladder repair device, sphincter muscle repair device, suture anchor, soft suture anchor, bone anchor, ligament repair device, ligament augmentation device, ligament graft, anterior cruciate ligament repair device, tendon repair device, tendon graft, tendon augmentation device, rotator cuff repair device, meniscus repair device, meniscus regeneration device, articular cartilage repair device, osteochondral repair device, spinal fusion device, stent, coronary stent, cardiovascular stent peripheral stent, ureteric stent, urethral stent, urology stent, gastroenterology stent, nasal stent, ocular stent, neurology stent, stent graft, cardiovascular patch, vascular closure device, intracardiac septal defect repair device, atrial septal defect repair device, PFO (patent foramen ovale) closure devices, left atrial appendage (LAA) closure device, pericardial patch, vein valve, heart valve, vascular graft, myocardial regeneration device, periodontal mesh, guided tissue regeneration membrane for periodontal tissue, embolization device, anastomosis device, cell seeded device, controlled release device, drug delivery device, plastic surgery device, breast lift device, mastopexy device, breast reconstruction device, breast augmentation device, breast reduction device, devices for breast reconstruction following mastectomy with or without breast implants, facial reconstructive device, forehead lift device, brow lift device, eyelid lift device, face lift device, rhytidectomy device, thread lift device to lift and support sagging areas of the face, brow and/or neck, rhinoplasty device, device for malar augmentation, otoplasty device, neck lift device, mentoplasty device, cosmetic repair device, device for facial scar revision, and enclosures, pouches, holders, covers, clamshells, casings to hold implantable medical devices. 7. The device of claim 6, wherein the device is sterile and/or biocompatible. 8. The device of claim 6, wherein the device has been sterilized by ethylene oxide, electron beam irradiation or gamma irradiation and/or contains less than 20 endotoxin units. 9. The device of claim 8, wherein the device is a mesh produced by a method comprising: (a) knitting or weaving the monofilament fiber or multifilament yarn and (b) packaging and sterilizing the mesh. 10. The device of claim 9 wherein the mesh can withstand a burst pressure of at least 0.1 kPa. 11. The device of claim 6, wherein the device is a braid or tape with a breaking load between a breaking load greater than 1.0, 10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0 or 80.0 kgf and less than or equal to 85.2 kgf. 12. The device of claim 6, wherein the device is a braid, with a diameter less than 0.8 mm, and a breaking load between a breaking load greater than 22 kgf and less than or equal to 26.2 kgf, or a tape with a thickness less than 0.52 mm and a width less than 3.75 mm, and a breaking load between 35 kgf and 85.2 kgf. 13. The medical device of claim 6, further comprising one or more of the following: plasticizer, nucleant, dye, medical marker, bioactive agent, therapeutic agent, antimicrobial agent, diagnostic agent, prophylactic agent, protein, peptide, antibody, polysaccharide, glycoprotein, lipid, lipoprotein, nucleic acid molecule, inorganic or organic synthetic molecule, contrast agent, radiopaque marker, radioactive substance, hyaluronic acid or derivative thereof, collagen, hydroxyapatite, synthetic polymer, natural polymer or one or more absorbable polymers derived from glycolic acid, glycolide, lactic acid, lactide, 1,4-dioxanone, trimethyl carbonate, ε-caprolactone. 14. The medical device of claim 13, wherein the antimicrobial agent is selected from one or more of the following: rifampin; minocycline and its hydrochloride, sulfate, or phosphate salt; triclosan; chlorhexidine; vancomycin and its hydrochloride, sulfate, or phosphate salt; tetracycline and its hydrochloride, sulfate, or phosphate salt, and derivatives; gentamycin; cephalosporin antimicrobials; aztreonam; cefotetan and its disodium salt; loracarbef; cefoxitin and its sodium salt; cefazolin and its sodium salt; cefaclor; ceftibuten and its sodium salt; ceftizoxime; ceftizoxime sodium salt; cefoperazone and its sodium salt; cefuroxime and its sodium salt; cefuroxime axetil; cefprozil; ceftazidime; cefotaxime and its sodium salt; cefadroxil; ceftazidime and its sodium salt; cephalexin; cefamandole nafate; cefepime and its hydrochloride, sulfate, and phosphate salt; cefdinir and its sodium salt; ceftriaxone and its sodium salt; cefixime and its sodium salt; cefpodoxime proxetil; meropenem and its sodium salt; imipenem and its sodium salt; cilastatin and its sodium salt; azithromycin; clarithromycin; dirithromycin; erythromycin and hydrochloride, sulfate, or phosphate salts, ethylsuccinate, and stearate forms thereof, clindamycin; clindamycin hydrochloride, sulfate, or phosphate salt; lincomycin and hydrochloride, sulfate, or phosphate salt thereof, tobramycin and its hydrochloride, sulfate, or phosphate salt; streptomycin and its hydrochloride, sulfate, or phosphate salt; neomycin and its hydrochloride, sulfate, or phosphate salt; acetyl sulfisoxazole; colistimethate and its sodium salt; quinupristin; dalfopristin; amoxicillin; ampicillin and its sodium salt; clavulanic acid and its sodium or potassium salt; penicillin G; penicillin G benzathine, or procaine salt; penicillin G sodium or potassium salt; carbenicillin and its disodium or indanyl disodium salt; piperacillin and its sodium salt; ticarcillin and its disodium salt; sulbactam and its sodium salt; moxifloxacin; ciprofloxacin; ofloxacin; levofloxacins; norfloxacin; gatifloxacin; trovafloxacin mesylate; alatrofloxacin mesylate; trimethoprim; sulfamethoxazole; demeclocycline and its hydrochloride, sulfate, or phosphate salt; doxycycline and its hydrochloride, sulfate, or phosphate salt; oxytetracycline and its hydrochloride, sulfate, or phosphate salt; chlortetracycline and its hydrochloride, sulfate, or phosphate salt; metronidazole; dapsone; atovaquone; rifabutin; linezolide; polymyxin B and its hydrochloride, sulfate, or phosphate salt; sulfacetamide and its sodium salt; clarithromycin; and silver ions, salts, and complexes. 15. A method of using the device of claim 6, comprising implanting the device in the body of a patient in need thereof. 16. The method of claim 15, wherein the device is implanted using an open procedure, arthroscopic procedure, laparoscopic procedure, or delivered from a preconfigured delivery unit that may or may not be under tension. 17. The method of claim 15, wherein the device is a suture anchor, bone anchor, soft suture anchor, suture, tape, mesh or patch, and is preloaded for delivery. 18. The method of claim 15, wherein the device is used in orthopedic surgery, ligament and tendon repairs, Bankart lesion repair, SLAP lesion repair, acromion-clavicular repair, capsular shift/capsulolabral reconstruction, deltoid repair, Labral repair of the shoulder, Capsular/Labral Repairs of the Hip, rotator cuff tear repair, biceps tenodesis, foot and ankle medial/lateral repair and reconstruction, mid- and forefoot repair, Hallux valgus reconstruction, metatarsal ligament/tendon repair and reconstruction, Achilles tendon repair, ulnar or radial collateral ligament reconstruction, lateral epicondylitis repair, biceps tendon reattachment, knee extra-capsular repair, iliotibial band tenodesis, patellar tendon repair, vastus medialis obliquus (VMO) advancement, knee joint capsule closure, hand and wrist collateral ligament repair, scapholunate ligament reconstruction, tendon transfers in phalanx, volar plate reconstruction, acetabular labral repair, anterior ligament repair, spinal repair, fracture fixation, cardiovascular surgery, general surgery, gastric surgery, bowel surgery, abdominoplasty, plastic, cosmetic and reconstructive surgery, forehead lifting, brow lifting, eyelid lifting, facelift, neck lift, breast lift, lateral canthopexy, elevation of the nipple, breast reconstruction, breast reduction, breast augmentation, mastopexy, pelvic floor reconstruction, cystocele and rectocele repair, low anterior resection, urethral suspension, obstetrics and gynecological surgery, Nissen Fundoplication, myomectomy, hysterectomy, sacrolpopexy, cesarean delivery, hernia repair, general soft tissue approximation and ligation, wound closure reduction of wide scars, wound hernia repair, hemostasis, anastomosis, abdominal closure, laparoscopic procedures, partial nephrectomy, and implantation of cardiac rhythm management (CRM) devices, including pacemakers, defibrillators, generators, neurostimulators, ventricular access devices, infusion pumps, devices for delivery of medication and hydration solutions, intrathecal delivery systems, pain pumps, and other devices to provide drugs or electrical stimulation to a body part. 19. The multifilament yarn of claim 1, wherein the yarn has a denier per filament between 1.7 and 6. 20. The monofilament fiber of claim 1 wherein the monofilament fiber has been drawn at a temperature below 45° C., before being drawn at a temperature above the melt temperature of the fiber. 21. The multifilament yarn of claim 1, wherein the yarn has a tenacity greater than 10 grams per denier. 22. The multifilament yarn of claim 1, wherein the yarn has been oriented in a multi-stage orientation process, wherein the yarn is hot drawn in at least one stage. 23. The multifilament yarn of claim 22, wherein the yarn is cold drawn in the first stage of the multi-stage orientation process. 24. The multifilament yarn of claim 1, wherein the retained breaking load of the yarn decreases less than 65% after implantation for two weeks. 25. The multifilament yarn or monofilament fiber of claim 1, further comprising an additive wherein the additives are plasticizers, nucleants, compatibilizers, porogens, radiolabelled substances, imaging agents, radiopaque markers, contrast agents, dyes, bioactive agents, absorbable polymers, natural polymers, and synthetic polymers. 26. The multifilament yarn or monofilament fiber of claim 1, wherein the weight average molecular weight of the 4-hydroxybutyrate polymer or copolymer is between 50 kD and 1,200 kD. 27. The multifilament fiber of claim 1 with a tensile strength between 800 MPa and 1,500 MPa. 28. The multifilament fiber of claim 1 with a tensile strength between 1000 MPa and 1,500 MPa. 29. A method for preparing the multifilament yarn or monofilament fiber of claim 14 comprising (a) spinning a multifilament yarn or monofilament fiber comprising a 4-hydroxybutyrate polymer or copolymer, and (b) cold drawing the multifilament yarn or monofilament fiber, wherein the multifilament yarn or monofilament fiber is hot drawn after cold drawing at a temperature above the melt temperature of the polymer or copolymer, wherein the monofilament fiber is cold drawn with an orientation ratio of 3 to 4, and then hot drawn in one or more subsequent draws. 30. The method of claim 1, wherein the multifilament yarn is cold drawn with an orientation ratio of 2 to 6, and then hot drawn in one or more subsequent draws to yield a yarn with a tenacity of at least 8.1 grams per denier, preferably at least 8.5 grams per denier, more preferably at least 9.0 grams per denier, and even more preferably greater than 9.5 grams per denier and the monofilament fiber is cold drawn with an orientation ratio of 3 to 4, and then hot drawn in one or more subsequent draws. 31. The method of claim 30, further comprising relaxing and/or annealing the fiber. 32. The method of claim 1, wherein the multifilament yarn or monofilament fiber are spun from a polymer or copolymer with a weight average molecular weight between 50 kDa and 1,200 kDa measured by gel permeation chromatography relative to polystyrene. 33. The method of claim 1, wherein the monofilament fiber has one or more of the following properties: an elongation to break between 15% and 120%; tensile strength between 500 MPa and 1500 MPa; and a Young's modulus less than 2 GPa.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (144)
Stack Richard S. (Chapel Hill NC) Klopovic Zenaida P. (Durham NC), Absorbable stent.
Urquhart John (Palo Alto CA) Chandrasekaran Santosh Kumar (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Bandage for transdermally administering scopolamine to prevent nausea.
Della Valle Francesco,ITX ; Romeo Aurelio,ITX ; Callegaro Lanfranco,ITX, Biodegradable and bioabsorbable guide channels for use in nerve treatment and regeneration.
Dunn Richard L. (451 Boardwalk Dr. RLD ; Apt. 501 Fort Collins CO 80526) English James P. (2500 Melinda Cir. Birmingham AL 35214) Cowsar Donald R. (4657 Round Forest Dr. Birmingham AL 35213) Vanderbi, Biodegradable in-situ forming implants and methods of producing the same.
Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Vanderbilt David D. (Birmingham AL), Biodegradable in-situ forming implants and methods of producing the same.
Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Vanderbilt David P. (Birmingham AL), Biodegradable in-situ forming implants and methods of producing the same.
Dehennau Claude (Waterloo BEX) Depireux Thierry (Waterloo BEX) Fleche Guy (Hazebrouck FRX) Gosset Serge (Lestrem FRX) Videau Didier (Lille FRX), Biodegradable moulding compositions comprising a starch, a biodegradable polyester, and a salt of a hydroxycarboxylic ac.
Mao, Hai-Quan; Leong, Kam W.; Dang, Wenbin; Lo, Hungnan; Zhao, Zhong; Nowotnik, David P.; English, James P., Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same.
Huisman Gjalt W. ; Skraly Frank ; Martin David P. ; Peoples Oliver P., Biological systems for manufacture of polyhydroxyalkanoate polymers containing 4-hydroxyacids.
Martin, David P.; Rizk, Said; Montcrieff, Jon I.; Connelly, Dennis W., Coatings for the manufacture and application of polyhydroxyalkanoate medical devices.
Hlavacek Robert A. (New Haven CT) Dumican Barry L. (Fairfield CT) McCusker Edward J. (Fairfield CT), Flat braided ligament or tendon implant device having texturized yarns.
Wallace Donald G. (Menlo Park) McMullin Hugh (Pacifica) Chu George (Cupertino CA), Injectable ceramic compositions and methods for their preparation and use.
Scopelianos Angelo G. ; Arnold Steven C. ; Bezwada Rao S. ; Roller Mark B. ; Huxel Shawn T., Injectable microdipersions for soft tissue repair and augmentation.
Trml Pertti (Tampere FIX) Rokkanen Pentti (Helsinki FIX) Laiho Juha (Tampere FIX) Tamminmki Markku (Tampere FIX) Vainionp Seppo (Helsinki FIX), Material for osteosynthesis devices.
Williams, Simon F.; Martin, David P.; Gerngross, Tillman; Horowitz, Daniel M., Medical device containing polyhydroxyalkanoate treated with oxidizing agent to remove endotoxin.
Martin, David P.; Rizk, Said; Ho, Kicherl; Williams, Simon F., Medical devices containing melt-blown non-wovens of poly-4-hydroxybutyrate and copolymers thereof.
Snell Kristi D. ; Hogan Scott A. ; Sim Sang Jun,KRX ; Sinskey Anthony J. ; Rha Chokyun, Method for controlling molecular weight of polyhydroxyalkanoates.
Williams,Simon F.; Martin,David P.; Gerngross,Tillman; Horowitz,Daniel M., Method for making devices using polyhydroxyalkanoate having pyrogen removed.
Williams, Simon F.; Martin, David P.; Gerngross, Tillman; Horowitz, Daniel M., Method of forming medical devices having pyrogen removed for in vivo application.
Peoples Oliver P. (Arlington MA) Gerngross Tillman U. (Cambridge MA) Sinskey Anthony J. (Boston MA), Overproduction and purification of soluble PHA synthase.
Gallagher Francis G. (Wilmington DE) Hamilton Cathy J. (Wilmington DE) Hansen Steven M. (Kinston NC) Shin Hyunkook (Wilmington DE) Tietz Raymond F. (Wilmington DE), Polyesters and their use in compostable products such as disposable diapers.
Witholt Bernard (Eelde NLX) Lageveen Roland G. (Groningen NLX), Process for producing polyesters by fermentation: a process for producing optically active carboxylic acids and esters:.
Williams Simon F. ; Martin David P. ; Gerngross Tillman ; Horowitz Daniel M., Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation.
Gogolewski Sylwester (Alvaneu CHX) Perren Stephan M. (Davos CHX), Resorbable fixation device with controlled stiffness for treating bodily material in vivo and introducer therefor.
Mahmood, Tahir; Riesle, Jens Uwe; van Blitterswijk, Clemens Antoni, Scaffold for tissue engineering cartilage having outer surface layers of copolymer and ceramic material.
Enscore David J. (Sunnyvale CA) Campbell Patricia S. (Palo Alto CA) Osborne James L. (Mountain View CA) Smart Melinda K. (Sunnyvale CA) Yum Su I. (Los Altos CA), Subsaturated transdermal therapeutic system having improved release characteristics.
Trml Pertti (Reikonkatu 7 C 7 ; SF-33730 Tampere FIX) Rokkanen Pentti (Marjaniemenranta 29 ; SF-00930 Helsinki FIX) Vainionp Seppo (Orapihlajhatie 21-27 B 12 ; SF-00320 Helsinki FIX) Laiho Juha (Pirk, Surgical materials and devices.
Chandrasekaran Santosh K. (Palo Alto CA) Darda Siegfried (Ingelheim am Rhein CA DEX) Michaels Alan S. (Atherton CA) Cleary Gary W. (Palo Alto CA), Therapeutic system for administering clonidine transdermally.
Gale Robert M. (Los Altos CA) Goetz Victor (Palo Alto CA) Lee Eun S. (Redwood City CA) Taskovich Lina T. (Palo Alto CA) Yum Su I. (Los Altos CA), Transdermal administration of fentanyl and device therefor.
Gale Robert M. (Los Altos CA) Enscore David J. (Sunnyvale CA) Nedberge Diane E. (Los Altos CA) Nelson Melinda (Sunnyvale CA) Cheng Yu-Ling (Cupertino CA) Libicki Shari B. (Palo Alto CA), Transdermal administration of progesterone, estradiol esters, and mixtures thereof.
Nedberge Diane E. (Los Altos CA) Campbell Patricia S. (Palo Alto CA) Gale Robert M. (Los Altos CA) Yum Su I. (Los Altos CA), Transdermal contraceptive formulations.
Chen Yu-Ling (Cupertino CA) Chun Leslie L. (Palo Alto CA) Enscore David J. (Sunnyvale CA), Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.